September 3, 2010 — The US Food and Drug Administration (FDA) has approved bimatoprost 0.01% ophthalmic solution (Lumigan; Allergan) for the first-line treatment of elevated intraocular pressure (IOP) ...
BRIDGEWATER, N.J., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. IRVINE, Calif. — The U.S. Food and Drug Administration ...
Bimatoprost ophthalmic solution 0.01% is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Kone continued ...
Firm projects Lumigan product sales will total $490–$510 million in 2010. FDA has approved Allergan’s Lumigan® 0.01% bimatoprost solution as first-line therapy for reducing intraocular pressure (IOP) ...
The Food and Drug Administration has approved Amneal’s bimatoprost ophthalmic solution 0.01% (2.5 ml, 5 ml and 7.5 ml), which is the generic of Allergan’s Lumigan. Bimatoprost ophthalmic solution 0.01 ...
Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that new nonclinical data on NCX 470 (0.1%) demonstrating greater intraocular pressure ...
We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...
Allergan, Inc. v. Sandoz Inc., No. 2014-1275, 2015 U.S. App. LEXIS 13616 (Fed. Cir. Aug. 4, 2015) (Before Lourie, Linn, and Hughes, J.) (Opinion for the court, Lourie ...
Addressing obviousness issues, the U.S. Court of Appeals for the Federal Circuit affirmed a lower court’s finding that patents were valid and infringed, despite undeniably including recitations ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. LONDON — Lumigan (AGN 192024, Allergan) once daily ...
In Allergan, Inc. v. Sandoz, Inc., the Federal Circuit affirmed the district court decision that upheld the validity of the Allergan patents relating to Lumigan® 0.01% glaucoma eye drops. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results